Gsa Capital Partners LLP Ac Immune Sa Transaction History

Gsa Capital Partners LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 11, 2022	SELL	$3.5 - $5.16 $255,661 - $376,917	-73,046 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$4.83 - $7.56 $352,812 - $552,227	73,046 New	73,046 $362,000
Q2 2020 Aug 11, 2020	SELL	$6.57 - $8.3 $110,376 - $139,440	-16,800 Closed	0 $0
Q1 2020 May 12, 2020	SELL	$4.24 - $9.89 $64,872 - $151,317	-15,300 Reduced 47.66%	16,800 $116,000
Q4 2019 Feb 12, 2020	BUY	$4.56 - $8.78 $15,959 - $30,729	3,500 Added 12.24%	32,100 $273,000
Q3 2019 Nov 12, 2019	BUY	$4.8 - $5.89 $137,280 - $168,454	28,600 New	28,600 $142,000
Q4 2018 Feb 12, 2019	SELL	$7.35 - $11.7 $101,437 - $161,471	-13,801 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$7.88 - $16.45 $108,751 - $227,026	13,801 New	13,801 $110,000

27.9M

150K

12.4K

Ticker ACIU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,413,504
Market Cap $224M
Description
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectiv...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.